- Compound for inhibiting SREBP-1 target point and application thereof
-
The invention belongs to the technical field of pharmacy. Specifically, the invention provides a compound for inhibiting an SREBP-1 target, and an isomer, a pharmaceutically acceptable salt or a hydrate thereof. The invention aims to provide a compound fo
- -
-
Paragraph 0067-0069
(2019/11/20)
-
- Pyrido-pyrimidines, its preparation and use
-
The invention discloses pyridopyrimidine compounds with a general formula (I), wherein Ar is aryl or heteroaryl; R1 is hydrogen, halogen, amino, heterocyclic group, alkyl, aminoalkyl, heterocyclic alkyl, aryl, heteroaryl, cyano, alkenyl or alkynyl; R2 is
- -
-
Paragraph 0181; 0182
(2017/06/21)
-
- Having a spiro ring substituent of aryl morpholine compound, its preparation and use
-
The invention discloses arylmorpholine compounds with spiro substituents. The arylmorpholine compounds are compounds having the following general formula (I), wherein X is N or CH; R1 is hydrogen, hydroxyl, alkoxy, halogen, amino, amido, acylamino, sulfam
- -
-
Paragraph 0159-0161
(2017/08/02)
-
- As the PI3K/mTOR inhibitor tricyclic compound, its preparation and use
-
The invention discloses a tricyclic compound as a PI3K/mTOR inhibitor. The tricyclic compound is a compound with the general formula (I) in the specification, wherein Ar is selected from aryl or heteroaryl; X, Y and Z are independently selected from O, CR2R3 and NR4 respectively; Q is selected from O, CR2R3 and NR4 or does not exists; R1 represents C1-C6 alkyl; n is selected from integers from 0 to 4; when n is more than or equal to 2, two R1 and a morpholine cycle can be combined into a combined cycle, a bridge cycle or a spiral cycle; R2 and R3 are selected from hydrogen and C1-C6 alkyl; R4 is selected from hydrogen, C1-C6 alkyl, C3-C7 cycloalkyl, heterocyclic radical, acyl and sulfonyl. The invention further discloses a perpetration method of the compound with the general formula (I) as well as a pharmaceutical composition and application of the compound with the general formula (I).
- -
-
Paragraph 0167; 0168; 0169
(2017/08/25)
-
- Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases
-
Tetra-substituted imidazoles were designed as dual inhibitors of c-Jun N-terminal kinase (JNK) 3 and p38α mitogen-activated protein (MAP) kinase. A library of 45 derivatives was prepared and evaluated in a kinase activity assay for their ability to inhibi
- Muth, Felix,Günther, Marcel,Bauer, Silke M.,D?ring, Eva,Fischer, Sabine,Maier, Julia,Drückes, Peter,K?ppler, Jürgen,Trappe, J?rg,Rothbauer, Ulrich,Koch, Pierre,Laufer, Stefan A.
-
supporting information
p. 443 - 456
(2015/07/27)
-
- PI3K/MTOR KINASE INHIBITORS
-
6-morpholin-4-yl-pyrazolo[3,4-d]pyrimidine and 2-morpholin-4-yl-7H- pyrrolo[2,3-d]pyrimidine derivatives have unexpected drug properties as inhibitors of PI3 and/or mTOR kinases and are useful in treating disorders related to abnormal PI3K/mT0R activities such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders.
- -
-
Page/Page column 67; 68
(2010/06/15)
-